11 Hormone Aptamers in Endocrine-Related Diseases
349
84. Hao Z, Zhu Y, Wang X, Rotti PG, DiMarco C, Tyler SR, Zhao X, Engelhardt JF, Hone J, Lin
Q (2017) Real-Time monitoring of insulin using a graphene field-effect transistor aptameric
nanosensor. ACS Appl Mater Interfaces 9(33):27504–27511. https://doi.org/10.1021/acsami.
7b07684
85. Lindstrom LS, Yau C, Czene K, Thompson CK, Hoadley KA, Van’t Veer LJ, Balassanian
R, Bishop JW, Carpenter PM, Chen YY, Datnow B, Hasteh F, Krings G, Lin F, Zhang Y,
Nordenskjold B, Stal O, Benz CC, Fornander T, Borowsky AD, Esserman LJ, Group STOT
(2018) Intratumor heterogeneity of the estrogen receptor and the long-term risk of fatal breast
cancer. J Natl Cancer Inst 110(7):726–733. https://doi.org/10.1093/jnci/djx270
86. Saha Roy S, Vadlamudi RK (2012) Role of estrogen receptor signaling in breast cancer
metastasis. Int J Breast Cancer 2012:654698. https://doi.org/10.1155/2012/654698
87. Marino M, Galluzzo P, Ascenzi P (2006) Estrogen signaling multiple pathways to impact gene
transcription. Curr Genomics 7(8):497–508. https://doi.org/10.2174/138920206779315737
88. Dutertre M, Smith CL (2000) Molecular mechanisms of selective estrogen receptor modulator
(SERM) action. J Pharmacol Exp Ther 295(2):431–437
89. Sett A, Borthakur BB, Sharma JD, Kataki AC, Bora U (2017) DNA aptamer probes for
detection of estrogen receptor alpha positive carcinomas. Trans Res J Lab Clin Med 183:104–
120.e102. https://doi.org/10.1016/j.trsl.2016.12.008
90. Ahirwar R, Vellarikkal SK, Sett A, Sivasubbu S, Scaria V, Bora U, Borthakur BB, Kataki AC,
Sharma JD, Nahar P (2016) Aptamer-Assisted detection of the altered expression of estrogen
receptor alpha in human breast cancer. PLoS ONE 11(4):e0153001. https://doi.org/10.1371/
journal.pone.0153001
91. De Schrijver E, Brusselmans K, Heyns W, Verhoeven G, Swinnen JV (2003) RNA
interference-mediated silencing of the fatty acid synthase gene attenuates growth and
induces morphological changes and apoptosis of LNCaP prostate cancer cells. Cancer Res
63(13):3799–3804
92. Knudsen KE, Scher HI (2009) Starving the addiction: new opportunities for durable
suppression of AR signaling in prostate cancer. Clin Cancer Res 15(15):4792–4798
93. Haelens A, Verrijdt G, Callewaert L, Peeters B, Rombauts W, Claessens F (2001) Androgenreceptor-specific DNA binding to an element in the first exon of the human secretory
component gene. Biochem J 353(Pt 3):611–620
94. Kouhpayeh S, Einizadeh AR, Hejazi Z, Boshtam M, Shariati L, Mirian M, Darzi L, Sojoudi
M, Khanahmad H, Rezaei A, Chen R, Zhao Y, Huang Y, Yang Q, Zeng X, Jiang W, Liu
J, Thrasher JB, Forrest ML, Li B (2016) Antiproliferative effect of a synthetic aptamer
mimicking androgen response elements in the LNCaP cell line Nanomicellar TGX221 blocks
xenograft tumor growth of prostate cancer in nude mice. Cancer Gene Ther 23(8):254–257.
https://doi.org/10.1038/cgt.2016.26
95. Reeb CA, Gerlach C, Heinssmann M, Prade I, Ceraline J, Roediger J, Roell D, Baniahmad A (2011) A designed cell-permeable aptamer-based corepressor peptide is highly
specific for the androgen receptor and inhibits prostate cancer cell growth in a vectorfree mode. Endocrinology 152(6):2174–2183. https://doi.org/10.1002/pros.2294110.1210/
en.2011-0149
96. DeFronzo RA, Ferrannini E, Groop L, Henry RR, Herman WH, Holst JJ, Hu FB, Kahn CR,
Raz I, Shulman GI, Simonson DC, Testa MA, Weiss R (2015) Type 2 diabetes mellitus. Nat
Rev Dis Prim 1:15019. https://doi.org/10.1038/nrdp.2015.19
97. Klussmann S, Nolte A, Bald R, Erdmann VA, Fürste JP (1996) Mirror-image RNA that binds
D-adenosine. Nat Biotechnol 14(9):1112–1115. https://doi.org/10.1038/nbt0996-1112
98. Vater A, Klussmann S (2015) Turning mirror-image oligonucleotides into drugs: the evolution
of Spiegelmer(®) therapeutics. Drug Discov Today 20(1):147–155. https://doi.org/10.1016/
j.drudis.2014.09.004
99. Kulkarni O, Eulberg D, Selve N, Zollner S, Allam R, Pawar RD, Pfeiffer S, Segerer
S, Klussmann S, Anders HJ (2009) Anti-Ccl2 Spiegelmer permits 75% dose reduction
of cyclophosphamide to control diffuse proliferative lupus nephritis and pneumonitis in
MRL-Fas(lpr) mice. J Pharmacol Exp Ther 328(2):371–377. https://doi.org/10.1124/jpet.108.
142711
349
84. Hao Z, Zhu Y, Wang X, Rotti PG, DiMarco C, Tyler SR, Zhao X, Engelhardt JF, Hone J, Lin
Q (2017) Real-Time monitoring of insulin using a graphene field-effect transistor aptameric
nanosensor. ACS Appl Mater Interfaces 9(33):27504–27511. https://doi.org/10.1021/acsami.
7b07684
85. Lindstrom LS, Yau C, Czene K, Thompson CK, Hoadley KA, Van’t Veer LJ, Balassanian
R, Bishop JW, Carpenter PM, Chen YY, Datnow B, Hasteh F, Krings G, Lin F, Zhang Y,
Nordenskjold B, Stal O, Benz CC, Fornander T, Borowsky AD, Esserman LJ, Group STOT
(2018) Intratumor heterogeneity of the estrogen receptor and the long-term risk of fatal breast
cancer. J Natl Cancer Inst 110(7):726–733. https://doi.org/10.1093/jnci/djx270
86. Saha Roy S, Vadlamudi RK (2012) Role of estrogen receptor signaling in breast cancer
metastasis. Int J Breast Cancer 2012:654698. https://doi.org/10.1155/2012/654698
87. Marino M, Galluzzo P, Ascenzi P (2006) Estrogen signaling multiple pathways to impact gene
transcription. Curr Genomics 7(8):497–508. https://doi.org/10.2174/138920206779315737
88. Dutertre M, Smith CL (2000) Molecular mechanisms of selective estrogen receptor modulator
(SERM) action. J Pharmacol Exp Ther 295(2):431–437
89. Sett A, Borthakur BB, Sharma JD, Kataki AC, Bora U (2017) DNA aptamer probes for
detection of estrogen receptor alpha positive carcinomas. Trans Res J Lab Clin Med 183:104–
120.e102. https://doi.org/10.1016/j.trsl.2016.12.008
90. Ahirwar R, Vellarikkal SK, Sett A, Sivasubbu S, Scaria V, Bora U, Borthakur BB, Kataki AC,
Sharma JD, Nahar P (2016) Aptamer-Assisted detection of the altered expression of estrogen
receptor alpha in human breast cancer. PLoS ONE 11(4):e0153001. https://doi.org/10.1371/
journal.pone.0153001
91. De Schrijver E, Brusselmans K, Heyns W, Verhoeven G, Swinnen JV (2003) RNA
interference-mediated silencing of the fatty acid synthase gene attenuates growth and
induces morphological changes and apoptosis of LNCaP prostate cancer cells. Cancer Res
63(13):3799–3804
92. Knudsen KE, Scher HI (2009) Starving the addiction: new opportunities for durable
suppression of AR signaling in prostate cancer. Clin Cancer Res 15(15):4792–4798
93. Haelens A, Verrijdt G, Callewaert L, Peeters B, Rombauts W, Claessens F (2001) Androgenreceptor-specific DNA binding to an element in the first exon of the human secretory
component gene. Biochem J 353(Pt 3):611–620
94. Kouhpayeh S, Einizadeh AR, Hejazi Z, Boshtam M, Shariati L, Mirian M, Darzi L, Sojoudi
M, Khanahmad H, Rezaei A, Chen R, Zhao Y, Huang Y, Yang Q, Zeng X, Jiang W, Liu
J, Thrasher JB, Forrest ML, Li B (2016) Antiproliferative effect of a synthetic aptamer
mimicking androgen response elements in the LNCaP cell line Nanomicellar TGX221 blocks
xenograft tumor growth of prostate cancer in nude mice. Cancer Gene Ther 23(8):254–257.
https://doi.org/10.1038/cgt.2016.26
95. Reeb CA, Gerlach C, Heinssmann M, Prade I, Ceraline J, Roediger J, Roell D, Baniahmad A (2011) A designed cell-permeable aptamer-based corepressor peptide is highly
specific for the androgen receptor and inhibits prostate cancer cell growth in a vectorfree mode. Endocrinology 152(6):2174–2183. https://doi.org/10.1002/pros.2294110.1210/
en.2011-0149
96. DeFronzo RA, Ferrannini E, Groop L, Henry RR, Herman WH, Holst JJ, Hu FB, Kahn CR,
Raz I, Shulman GI, Simonson DC, Testa MA, Weiss R (2015) Type 2 diabetes mellitus. Nat
Rev Dis Prim 1:15019. https://doi.org/10.1038/nrdp.2015.19
97. Klussmann S, Nolte A, Bald R, Erdmann VA, Fürste JP (1996) Mirror-image RNA that binds
D-adenosine. Nat Biotechnol 14(9):1112–1115. https://doi.org/10.1038/nbt0996-1112
98. Vater A, Klussmann S (2015) Turning mirror-image oligonucleotides into drugs: the evolution
of Spiegelmer(®) therapeutics. Drug Discov Today 20(1):147–155. https://doi.org/10.1016/
j.drudis.2014.09.004
99. Kulkarni O, Eulberg D, Selve N, Zollner S, Allam R, Pawar RD, Pfeiffer S, Segerer
S, Klussmann S, Anders HJ (2009) Anti-Ccl2 Spiegelmer permits 75% dose reduction
of cyclophosphamide to control diffuse proliferative lupus nephritis and pneumonitis in
MRL-Fas(lpr) mice. J Pharmacol Exp Ther 328(2):371–377. https://doi.org/10.1124/jpet.108.
142711